3 legs20 Jun 2016 13:26
Good to see you soldiering on. we will wonder how far 554 can go -unfortunately after weve gone eh?
like weve said all along-554 is unique, novel and there is nothing around or in the pipelines that can touch it for its holy grail-fev1 - more than 15% for a duration and no side effects of note, unlike its mainstream, competitors, and other drugs being trialled, who all fall short of 554's astounding results, to date.
well done vrp. ill happily take dilution of share issue at this stage than take an early door partnership, jv or buyout which will not have given us long term value in a multi billion $$ market, should 554 make it to production which we believe it will.
tier one pharmas will take note yet again.
copd/cf-and not to mention other parts of the copd tree yet to be explored fully, bronchiectasis, atalectasis and other evil components that run with copd as it develops towards end stage-emphysema and more.
as log as tobacco is grown there will be a need for 554.
todays news reflects the usa market with europe but figures quoted to date do not reflect the figures yet to come from far east-china etc which is possibly a bigger market than usa.
gl all
Corbs :-) im jmo dyoR and read the great work over on advfn vrp bbchat thread, some awesome research posters there who know their sabas from their lamas!!
Breathe easy 3 legged